Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.66+0.67 (+4.79%)
At close: 4:00PM EDT
14.00 -0.66 (-4.50%)
After hours: 06:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close13.99
Open14.39
Bid14.01 x 1100
Ask14.64 x 1400
Day's Range13.76 - 14.68
52 Week Range12.12 - 22.91
Volume347,528
Avg. Volume295,051
Market Cap2.27B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-8.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.09
  • GlobeNewswire

    atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

    atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health careNEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai Impact has been develo

  • GlobeNewswire

    atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

    NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications. PsyProtix takes a precision

  • GlobeNewswire

    DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

    NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). The trial has commenced enrollment and dosing of recreational drug users and healthy volunteers in the Phase 1 segment of the study at the Manchester clinical unit of MAC